Grifols (GRFS) Long-Term Investments (2009 - 2025)
Grifols (GRFS) posted Long-Term Investments of $112.9 million for Q4 2025, up 53.14% quarter-over-quarter from $73.7 million in Q4 2024, and up 53.14% year-on-year from $73.7 million in Q4 2024.
Grifols (GRFS) Long-Term Investments (2009 - 2025) Analysis & Trends
Grifols (GRFS) has reported Long-Term Investments for 16 consecutive years, with $112.9 million the latest figure, recorded in Q4 2025.
- Long-Term Investments for Q4 2025 came in at $112.9 million, up 53.14% year-over-year; the trailing twelve-month figure through Dec 2025 was $112.9 million (up 53.14% YoY), and the FY2025 annual result was $112.9 million, up 1781.87% from the prior year.
- Long-Term Investments was $112.9 million for Q4 2025 at Grifols, up from $73.7 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $1.8 billion in Q4 2021 and troughed at $73.7 million in Q4 2024.
- Average Long-Term Investments over 5 years is $786.5 million, with a median of $453.0 million recorded in 2023.
- Year-over-year, Long-Term Investments surged 423.86% in 2021 and sank 83.72% in 2024.
- Over 5 years, Long-Term Investments stood at $1.8 billion in 2021, then dropped by 13.39% to $1.5 billion in 2022, then sank by 70.36% to $453.0 million in 2023, then tumbled by 83.72% to $73.7 million in 2024, then soared by 53.14% to $112.9 million in 2025.
- Per Business Quant data, the three most recent Long-Term Investments figures were $112.9 million in Q4 2025, $73.7 million in Q4 2024, and $453.0 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 3.12 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 268.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -12.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 1.11 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 983.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 1.63 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | -24.00 Mn |
| 10 | Grifols | - | - | - | 112.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 112.91 Mn |
| Dec 31, 2024 | 73.73 Mn |
| Dec 31, 2023 | 452.97 Mn |
| Dec 31, 2022 | 1.53 Bn |
| Dec 31, 2021 | 1.76 Bn |
| Dec 31, 2020 | -544.88 Mn |
| Sep 30, 2020 | 194.29 Mn |
| Mar 31, 2020 | 504.50 Mn |
| Dec 31, 2019 | 126.71 Mn |
| Sep 30, 2019 | 156.09 Mn |
| Mar 31, 2019 | 147.46 Mn |
| Dec 31, 2018 | 258.99 Mn |
| Sep 30, 2018 | 15.48 Mn |
| Jun 30, 2018 | 6.84 Mn |
| Mar 31, 2018 | 134.15 Mn |
| Dec 31, 2017 | 257.87 Mn |
| Jun 30, 2017 | 11.32 Mn |
| Dec 31, 2016 | 4.05 Mn |
| Sep 30, 2016 | -14.67 Mn |
| Jun 30, 2016 | -18.88 Mn |